Hostname: page-component-848d4c4894-cjp7w Total loading time: 0 Render date: 2024-07-04T03:56:18.667Z Has data issue: false hasContentIssue false

PW01-188 - Characterization Of Cariprazine (Rgh-188) D3/D2 Receptor Occupancy In Healthy Volunteers And Schizophrenic Patients By Positron Emission Tomography (Pet)

Published online by Cambridge University Press:  17 April 2020

I. Laszlovszky
Affiliation:
Medical Division, Gedeon Richter, Plc., Budapest, Hungary
A. Gage
Affiliation:
Clinical Research, CNS, Forest Research Institute, Inc., Jersey City, NJ, USA
M. Kapas
Affiliation:
Pharmacological and Drug Safety Research, Gedeon Richter, Plc., Budapest, Hungary
P. Ghahramani
Affiliation:
Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Inc., Jersey City, NJ, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

To evaluate the striatal D3/D2 receptor occupancy of cariprazine (RGH-188) in healthy volunteers and schizophrenic patients, and assess the correlation between cariprazine plasma concentration and receptor occupancy.

Methods

Single- (0.5 mg) or multiple-dose (1 mg/day, 14 days) cariprazine was administered to healthy adult males (N=5) in an open-label positron emission tomography (PET) study. In a separate open-label PET study, multiple-dose cariprazine (0.5-3.0 mg/day, 14 days) was administered to adult male schizophrenic patients (N=8). Healthy volunteers had 1 predose and 1 postdose raclopride PET scan; schizophrenic patients had 1 predose and up to 3 postdose fallypride scans. Cariprazine plasma concentrations were determined by LC-MS/MS.

Results

In healthy volunteers, single-dose cariprazine 0.5 mg resulted in low plasma concentration (0.1 ng/ml) and was associated with 12% maximum D3/D2 receptor occupancy; cariprazine 1 mg/day for 14 days resulted in cariprazine plasma concentrations of 2.3-3.4 ng/ml and >70% D3/D2 receptor occupancy. In schizophrenic patients, cariprazine 1.5 mg/day for 14 days resulted in cariprazine plasma concentrations of 2.5-3.4 ng/ml and >70% receptor occupancy; cariprazine 3.0 mg/day resulted in ≥90% occupancy. Predicted Emax values in schizophrenic patients approached 100% D3/D2 occupancy for dorsal and ventral striatum.

Conclusions

D3/D2 receptor occupancy in dorsal and ventral striatum was similar for cariprazine 1.0 mg/day in healthy volunteers and cariprazine 1.5 mg/day in schizophrenic patients. In both, higher receptor occupancy was associated with higher cariprazine plasma concentration. Cariprazine at 1.5 to 3.0 mg/day showed D3/D2 receptor occupancy within the predicted effective antipsychotic range.

Type
Psychotic disorders / Schizophrenia
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.